Navigation Links
Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma
Date:2/27/2009

EVRY, France, February 27 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, announced the results of its first set of data pertaining to Nova21027, its innovative BAK-free latanoprost formulation for glaucoma.

Novagali communicated about "Ocular safety comparison of a latanoprost cationic emulsion versus conventional formulations of prostaglandin analogues: an in vivo toxicity assay" at the 9th Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) held in Salzburg, Austria. The experimental work has been performed in collaboration with Professor Christophe Baudouin from the Quinze-Vingts National Ophthalmology Hospital and Science Faculty of Paris V, France. Acute toxicological studies confirmed the ocular surface toxicity of anti-glaucomatous eye drops containing benzalkonimum chloride (BAK) while Novagali's BAK-free cationic emulsion of latanoprost was well tolerated and did not induce any ocular surface damages upon stress conditions.

Nova21027 is a topical ocular BAK-free emulsion of latanoprost relying on Novasorb(R) patented cationic emulsions technology. The company achieved a product that present a safer profile than BAK-containing marketed products for glaucoma. This feature is of paramount importance taken into account that BAK exerts toxicity after long term use and that glaucoma is a chronic disease needing life-long daily treatment.

"It is now admitted that BAK has a deleterious effect especially in ocular surface diseases and after long-term or combination therapies. This state-of-the art BAK-free formulation of latanoprost demonstrated both efficacy and safety in various preclinical models" says Jerome Martinez, CEO of Novagali.

"Our innovative formulation is also stable at room temperature, which makes our product more convenient from production to patients," explains Jean-Sebastien Garrigue, director of research & development.

The company will present further data in May 2009 during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO, Fort-Lauderdale, FL).

About Novagali Pharma

Novagali Pharma is an ophthalmic pharmaceutical company that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), for treatment of vernal keratoconjunctivitis, Cyclokat(R), for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma is based in the Genopole biocluster in Evry (France).


'/>"/>
SOURCE Novagali Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... , May 30, 2016 ... report "Healthcare Biometrics Market by Technology (Single-factor ... Multifactor, Multimodal), Application (Workforce Management), End User ... 2021", published by MarketsandMarkets, the market is ... 2021 from USD 1,182.6 Million by 2016, ...
(Date:5/30/2016)... 30, 2016 LifeScienceIndustryResearch.com adds ... research report with comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
Breaking Medicine Technology:
(Date:5/31/2016)... , ... June 01, 2016 , ... A book about ... New Renaissance ” (published by Balboa Press AU) attempts to give readers the courage ... , β€œThe Divine has inspired and guided me throughout my life to learn ...
(Date:5/31/2016)... Hollywood, Fl (PRWEB) , ... May 31, 2016 ... ... the doors to its new Concussion Clinic serving South Florida. , The ... sports medicine, pediatric neurology, pediatric physical medicine and rehabilitation, pediatric neuropsychology and also ...
(Date:5/31/2016)... (PRWEB) , ... June 01, 2016 , ... ... β€œ Psoriasis and smoking: links and risks ”. , As corresponding author Professor ... on the relation between smoking habits and psoriasis. Smoking influences the onset and ...
(Date:5/31/2016)... ... ... adults often find themselves reaching for a cup of coffee, an energy drink, or even ... is a cup of Matcha green tea. Matcha is a premium green tea powder made ... early June to mid-July, when the leaves are the most tender. , Matcha ...
(Date:5/31/2016)... ... 2016 , ... Splashtop Inc., the worldwide leader in high performance cross-screen ... the leading provider of secure mobile remote access solution for Japan enterprises. ... access solution. Splashtop for CACHATTO will be available as an integrated add-on ...
Breaking Medicine News(10 mins):